登录新浪财经APP 搜索【信披】查看更多考评等级 南京医药于2025年10月10日发布关于以集中竞价交易方式回购公司股份的进展公告，披露了回购股份的 最新情况。 南京医药表示，将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号 ——回购股份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时及时履行 信息披露义务。投资者需注意投资风险。 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 点击查看公告原文>> 回购方案回顾 责任编辑：小浪快报 回购进展详情 截至公告披露日，累计已回购股数1629.9951万股，占总股本比例1.25% ，累计已回购金额8025.76万 元，实际回购价格区间在4.69元/股至5 ...

南京医药公告，南药转债自2025年7月1日起开始转股，截至2025年9月30日，累计转股金额为66000元， 累计因转股形成的股份数量为12875股，占南药转债转股前公司已发行股份总额的0.00098%。截至2025 年9月30日，尚未转股的南药转债金额为10.81亿元，占南药转债发行总量的99.9939%。2025年7月1日至 2025年9月30日，南药转债转股金额为66000元，因转股形成的股份数量为12875股。 ...

Group 1 - The company Nanjing Pharmaceutical (600713.SH) has received a notification from New Investment Group regarding a reduction in holdings of "Nanjing Pharmaceutical Convertible Bonds" [1] - The reduction occurred between September 1, 2025, and September 15, 2025, totaling 1,081,500 bonds [1] - This reduction represents 10.00% of the total issuance of the convertible bonds [1]

Group 1 - The core point of the news is the performance and characteristics of Nanjing Pharmaceutical's convertible bonds, which have a current price of 133.129 yuan and a conversion premium rate of 28.64% [1] - Nanjing Pharmaceutical's convertible bonds have a credit rating of "AA+" and a maturity of 6 years, with a coupon rate that increases over the years, starting from 0.20% in the first year to 2.00% in the sixth year [1] - The conversion price for the bonds is set at 5.12 yuan, with the conversion period starting on July 1, 2025 [1] Group 2 - Nanjing Pharmaceutical Co., Ltd. was established in 1951 and is one of the earliest listed companies in China's pharmaceutical distribution industry, currently operating as a regional leader in the sector [2] - The company reported a revenue of 14.2469 billion yuan for the first quarter of 2025, reflecting a year-on-year increase of 2.11%, and a net profit of 177.4 million yuan, which is an increase of 11.49% year-on-year [2] - As of March 2025, the shareholding structure of Nanjing Pharmaceutical is highly dispersed, with the top ten shareholders holding a combined 60.82% of shares and a total of 56,410 shareholders [2]

Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., is issuing its third short-term financing bond for 2024, with a total issuance amount of 50 million yuan [1] - The bond, named "24 Nanjing Pharmaceutical SCP003," has an interest rate of 1.8% and a maturity period of 269 days, with the principal and interest repayment date set for September 12, 2025 [1] - The bond's repayment amount is expected to be approximately 50.66329 million yuan, subject to final confirmation [1] Group 2 - The bond's funds will be transferred to the designated account of the Interbank Market Clearing House before the repayment date, and the clearing house will then distribute the funds to bondholders [1] - In case the repayment date falls on a public holiday, the payment will be postponed accordingly [1] - Bondholders must notify the Interbank Market Clearing House of any changes to their fund transfer paths before the repayment date to avoid any delays in receiving funds [1]

Group 1 - The report identifies a significant increase in the number of new convertible bonds listed recently, leading to heightened market attention towards new issuances [7][8] - Convertible bonds are categorized into four main types: white horse, value, small market cap, and balanced, each exhibiting distinct pricing characteristics and investment opportunities, necessitating differentiated strategies for new issuances [7][26] Group 2 - White horse convertible bonds are characterized by high initial valuations and a generally high conversion premium, indicating a low investment cost-effectiveness. The report advises against participating in new issuances or buying on the first day due to systemic valuation risks [7][12][26] - Value convertible bonds typically show low initial valuations, with some even trading below par. The report highlights that institutional demand can drive prices upward post-initial trading, suggesting active participation in new issuances and buying during sell-offs for optimal risk-reward ratios [13][17][26] Group 3 - Small market cap convertible bonds exhibit significant price volatility due to limited liquidity, often leading to extreme pricing deviations from fundamentals. The report recommends avoiding high-price chasing and waiting for a price correction after 4-6 months for potential value recovery opportunities [21][27] - Balanced convertible bonds present relatively rational pricing and moderate volatility, with the report suggesting participation in new issuances and buying during initial sell-offs to achieve stable returns within 1-2 months [25][27]

Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. is issuing convertible bonds to unspecified investors, with a total amount of RMB 1,081,491,000, to be used for various investment projects [3][16][18]. Group 1: Issuance Details - The company has received approval from its board and regulatory authorities for the issuance of 10,814,910 convertible bonds, each with a face value of RMB 100 [3][4]. - The net proceeds from the issuance amount to RMB 1,069,040,922.31, which has been verified by KPMG Huazhen [3][18]. - The bonds will have a maturity period of six years from the issuance date, with an annual interest rate starting at 0.20% in the first year [5][12]. Group 2: Bond Terms - The initial conversion price for the bonds is set at RMB 5.29 per share, subject to adjustments based on corporate actions such as stock dividends and capital increases [8][21]. - The company has the right to redeem the bonds at 108% of the face value after five trading days post-maturity if certain conditions are met [9][10]. - Holders of the bonds can sell them back to the company at face value plus accrued interest if the stock price falls below 70% of the conversion price during the last two interest years [10][11]. Group 3: Use of Proceeds - The total investment amount for the projects funded by the bond proceeds is RMB 118,665,520, with the shortfall to be covered by the company’s own funds [16][18]. - The company plans to allocate the raised funds to specific projects, ensuring that the actual net proceeds are utilized effectively [16][18]. Group 4: Shareholder Rights - Original shareholders will have priority in subscribing to the bonds based on their holdings as of the record date, with specific timelines for subscription and payment [14][16]. - The company will ensure that the rights of bondholders are protected and that any adjustments to the conversion price are communicated transparently [20][22].

Core Viewpoint - The announcement details the issuance and terms of the convertible bond "NanYao Convertible Bond" by Nanjing Pharmaceutical Co., Ltd, including its conversion price, issuance scale, and relevant procedures for bondholders [1][2][3]. Group 1: Issuance Overview - The convertible bond code is 110098 and the bond name is "NanYao Convertible Bond" [1]. - The total issuance amount is 1,081.49 million RMB, with each bond having a face value of 100 RMB [2]. - The bond has a term of 6 years, from December 25, 2024, to December 24, 2030 [2]. Group 2: Conversion Terms - The conversion price is set at 5.12 RMB per share [2][4]. - The conversion period starts from July 1, 2025, and ends on December 24, 2030 [2][3]. - The bond has a tiered interest rate structure, starting at 0.20% in the first year and increasing to 2.00% in the sixth year [2]. Group 3: Conversion Procedures - Bondholders can apply for conversion during the specified conversion period on trading days [3]. - The conversion process includes a mechanism for handling fractional shares and the calculation of the actual convertible bond quantity [3][4]. - Newly converted shares will have the same rights as existing shares [4]. Group 4: Adjustment of Conversion Price - The initial conversion price was set at 5.29 RMB per share, which has been adjusted to 5.12 RMB due to a cash dividend distribution [5][6]. - The conversion price can be adjusted based on various corporate actions, including stock dividends and cash dividends [6][8]. - The company has the right to propose downward adjustments to the conversion price if the stock price falls below certain thresholds [8][9]. Group 5: Redemption and Sale Rights - The company may redeem the unconverted bonds at 108% of the face value within five trading days after maturity [10]. - Bondholders have the right to sell back their bonds to the company if the stock price falls below 70% of the conversion price during the last two interest years [10][12]. - Additional sale rights are available if there are significant changes in the use of raised funds [12].

债券代码：110098 债券简称：南药转债 证券代码：600713 证券简称：南京医药 编号：ls2025-091 南京医药股份有限公司 关于因实施权益分派调整可转债转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 调整前转股价格：5.29 元/股 ? 调整后转股价格：5.12 元/股 ? "南药转债"本次转股价格调整实施日期：2025 年 6 月 30 日 限公司向不特定对象发行可转换公司债券注册的批复》（证监许可【2024】1736 号）， 核准南京医药股份有限公司（以下简称"公司"）本次可转换公司债券（以下简称"可 转债"）发行。公司向不特定对象发行可转债 10,814,910 张，每张面值为人民币 100 元，并于 2025 年 1 月 20 日在上海证券交易所上市交易（债券简称：南药转债，债券 代码：110098），初始转股价格为 5.29 元/股。 一、转股价格调整依据 公司股份回购专用证券账户持有股数）为基数分配利润，向全体股东每 10 股派发现金 红利 1.70 元（含税）。在 ...

Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., has announced the issuance of its first medium-term note for 2023, with a total issuance amount of 100,000 million yuan [1] - The bond, named "23 Nanjing Pharmaceutical MTN001," has an interest rate of 3.1% and a maturity date set for June 20, 2025 [1] - The main underwriters for this bond issuance are Bank of Communications Co., Ltd. and Industrial Bank Co., Ltd. [1] Group 2 - The bond's interest and principal repayment will be managed by the China Interbank Market Clearing House Co., Ltd., which will transfer funds to bondholders on the specified payment date [1] - In case the payment date falls on a public holiday, the payment will be postponed accordingly [1] - The company and the clearing house will not be liable for any losses incurred due to delays in fund transfers if bondholders fail to notify changes in their payment account in a timely manner [1]